Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | BCL2 | P10415 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28795418 | 1.00 | SCN9A (0.47) | SCN9ABCL2MMP13KLK5GSTP1 | |
| SCHEMBL16822431 | 0.93 | SCN9A (0.53) | SCN9ABCL2MMP13MCL1CTSS | |
| SCHEMBL16822432 | 0.93 | SCN9A (0.53) | SCN9ABCL2MMP13MCL1CTSS | |
| SCHEMBL3779708 | 0.84 | SCN9A (0.51) | SCN9ABCL2MMP13KLK5GSTP1 | |
| SCHEMBL15583641 | 0.83 | BCL2 (0.46) | SCN9ABCL2MMP13KLK5GSTP1 | |
| SCHEMBL15947606 | 0.76 | GSTP1 (0.52) | KLK5GSTP1GSTM2TACR1CTSS | |
| SCHEMBL2294118 | 0.76 | KLK5 (0.61) | SCN9ABCL2MMP13KLK5CTSS | |
| SCHEMBL29721250 | 0.76 | KLK5 (0.61) | SCN9ABCL2MMP13KLK5CTSS | |
| SCHEMBL29103443 | 0.76 | KLK5 (0.61) | SCN9ABCL2MMP13KLK5CTSS | |
| SCHEMBL2294112 | 0.76 | KLK5 (0.61) | SCN9ABCL2MMP13KLK5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175603-A1 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175603-A1 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-102482221-B | bicyclic and tricyclic compounds as KATII inhibitors | PFIZER INC. (US) | 2014-10-22 | — | — | CN | disclosed |
| WO-2013186666-A1 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| CN-102482221-A | Bicyclic and tricyclic compounds as KATII inhibitors | PFIZER | 2012-05-30 | — | — | CN | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | SCN9A 1463/4885BCL2 2249/4885MMP13 2551/4885 |
| US-20150175603-A1 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | KAT2A, KAT2B, KAT7 | SCN9A 1564/4885BCL2 3165/4885MMP13 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.